Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01159665
Other study ID # TG-MV-010
Secondary ID
Status Completed
Phase Phase 2
First received July 7, 2010
Last updated December 2, 2014
Start date July 2010
Est. completion date January 2011

Study information

Verified date April 2014
Source ThromboGenics
Contact n/a
Is FDA regulated No
Health authority Belgium: Federal Agency for Medicinal Products and Health Products
Study type Interventional

Clinical Trial Summary

To evaluate the pharmacokinetic properties of intravitreal ocriplasmin 125 µg dose when administered at different time-points prior to planned primary pars plana vitrectomy (PPV)


Description:

Open-label, ascending-exposure-time, single center trial in which a total of 36 subjects will be enrolled. The time to remove the vitreous will be recorded and a vitreous sample will be obtained at the beginning of vitrectomy for determination of ocriplasmin activity; 32 subjects will receive 125 μg ocriplasmin intravitreal injection prior to vitrectomy and 4 subjects will not receive ocriplasmin intravitreal injection prior to vitrectomy (control arm).

Study drug will be administered in the mid-vitreous by injection. The study eye will be examined after study drug injection to exclude retinal non-perfusion or other complications.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date January 2011
Est. primary completion date November 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female subjects aged = 18

- Eye disease for which a primary vitrectomy is indicated

- Best Corrected Visual Acuity (BCVA) of 20/800 or better in the non-study eye

- Written informed consent obtained from the subject prior to inclusion in the trial

Exclusion Criteria:

- Proliferative diabetic retinopathy.

- Subjects with any vitreous hemorrhage or any other vitreous opacification which precludes either of the following: visualization of the posterior pole by visual inspection OR adequate assessment of the macula by either Optical Coherence Tomography (OCT) and/or fluorescein angiogram in the study eye

- Aphakia in the study eye

- High myopia (more than 8D) in study eye (unless prior cataract extraction or refractive surgery that makes refraction assessment unreliable for myopia severity approximation, in which case axial length >28 mm is an exclusion).

- Subjects with history of rhegmatogenous retinal detachment in the either eye

- Subjects who have had ocular surgery, laser photocoagulation treatment, or intravitreal injection(s) in the study eye in the prior three months

- Subjects who have had laser photocoagulation to the macula in the study eye at any time

- Subjects with uncontrolled glaucoma in the study eye (defined as intraocular pressure = 26 mm Hg in spite of treatment with anti-glaucoma medication)

- Subjects with a history of uveitis in either eye.

- Subjects who are pregnant or of child-bearing potential not utilizing an acceptable form of contraception. Acceptable methods of birth control include intrauterine device, oral, implanted, or injected contraceptives, and barrier methods with spermicide.

- Subjects who, in the Investigators view, will not complete all visits and investigations

- Subjects who have participated in an investigational drug trial within the past 30 days

- Subjects who have previously participated in this trial

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
ocriplasmin
125µg ocriplasmin intravitreal injection
ocriplasmin
125µg ocriplasmin intravitreal injection
ocriplasmin
125µg ocriplasmin intravitreal injection
ocriplasmin
125µg ocriplasmin intravitreal injection
ocriplasmin
125µg ocriplasmin intravitreal injection

Locations

Country Name City State
Belgium University Hospital Leuven Leuven

Sponsors (1)

Lead Sponsor Collaborator
ThromboGenics

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Other Time Necessary to Remove the Vitreous From the Eye PPV was performed in all subjects. The time necessary to remove the vitreous from the eye, measured from first start of vitrectomy cutter till end of core vitrectomy phase, was calculated. From first start of vitrectomy cutter till the end of core vitrectomy phase No
Primary Ocriplasmin Activity Levels in Vitreous Samples Obtained at the Beginning of Vitrectomy. Vitreous samples were obtained at the beginning of vitrectomy in subjects at various times relative to ocriplasmin injection (post-injection), for the determination of ocriplasmin activity (Group 1 [5-30 minutes]; Group 2 [31-60 minutes]; Group 3 [2-4 hours]; Group 4 [24 hours ±2 hours]; Group 5 [7 days ±1 day]. Subjects in Group 6 (control) did not receive the ocriplasmin injection. 5-30 minutes, 31-60 minutes, 2-4 hours, 1 day, or 7 days after ocriplasmin injection No
See also
  Status Clinical Trial Phase
Terminated NCT04409808 - IRIS Alfa Clinical Trial A Monocentric, Academic Clinical Trial Safety Study of a Prototype of a New Vitrectomy Device. N/A
Active, not recruiting NCT04566237 - Objective Measurements of the Opacification of the Lens After Vitrectomy N/A
Completed NCT00532415 - Safety and Efficacy of Vitreous Delineating Agent During Vitrectomy Phase 3
Completed NCT04076072 - Beveled-Tip Versus(vs) Standard-Tip Vitrectomy Probe N/A
Not yet recruiting NCT03633266 - Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy N/A
Completed NCT00927628 - Macular Hole Reopening N/A
Not yet recruiting NCT03637283 - Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage N/A
Completed NCT01255293 - Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments N/A
Terminated NCT01023009 - Postoperative Evolution After Small Gauge Vitrectomy Without Eye Occlusion
Completed NCT00737022 - Macular Appearance After Diabetic Vitrectomy N/A
Completed NCT02644694 - PK Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing Vitrectomy Phase 1
Completed NCT03902795 - Functional and Morphological Results of Rhegmatogenous Retinal Detachment Treated With Vitrectomy
Completed NCT01319318 - Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy N/A
Not yet recruiting NCT04346095 - Oral Sedation in Vitreoretinal Surgery Phase 4
Completed NCT00685490 - Vitrectomy for Branch Retinal Vein Occlusion N/A
Completed NCT05446948 - Observation of the Efficacy of Different Vitrectomy Systems to Treat Proliferative Diabetic Retinopathy N/A
Completed NCT05710458 - Performance Comparison of the 25 Gauge 20,000cpm HYPERVIT Dual Blade vs. 10,000cpm ULTRAVIT Vitrectomy Cutter N/A
Terminated NCT02995746 - Intravitreal Dexamethasone Implant for Persistent Macular Thickening and Edema After Vitrectomy for Epiretinal Membrane N/A
Completed NCT03701542 - The Application of M-charts and Microperimetry for the Assessment of Visual Function in Patients After Vitrectomy Due to the Full Thickness Macular Hole.
Completed NCT00799227 - Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema Phase 2